Pharmacodynamics: Tylosin is a macrolide antibiotic that inhibits bacterial protein synthesis by reversibly binding to the 50S subunit of bacterial ribosomes, blocking transpeptide action and mRNA shift. This effect is basically limited to rapidly dividing bacteria and mycoplasma, and belongs to the fast-acting antibacterial agent during the growth period. This product is mainly effective against Gram positive bacteria and Mycoplasma, with weak effects on bacteria and strong effects on Mycoplasma. Sensitive Gram positive bacteria include Staphylococcus aureus (including penicillin resistant Staphylococcus aureus), pneumococcus, streptococcus, anthrax bacteria, Listeria monocytogenes, Clostridium putrescens, and Clostridium aeruginosa. Sensitive bacteria can develop resistance to tetracycline, while Staphylococcus aureus exhibits partial cross resistance to tetracycline and erythromycin.
Pharmacokinetics: Tylosin can be absorbed from the gastrointestinal tract after oral administration, and reaches its peak blood concentration in pigs one hour after oral administration. However, Tylosin phosphate is less absorbed. The concentration of Tylosin entering breast milk is about 20% of the serum concentration during the same period. Tylosin is excreted in its original form through urine and bile.

Mainly used for infections caused by Mycoplasma, Staphylococcus, Streptococcus, Enterococcus, Pasteurella multocida, Haemophilus influenzae, Spirochetes, etc. Good growth promoting effect, continuous low dose, not only prevents diseases, but also significantly promotes animal production, shortens feeding cycle, and improves feed conversion rate